Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the American Association for Cancer Research, Verily’s Parkinson’s dataset, the ...

Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to ...

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

The three stocks listed here below all pay more than a 3% dividend yield. Many stocks have been falling this year, and if you ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.

We recently published a list of Billionaire Cliff Asness’ 10 Stock Picks with Huge Upside Potential. In this article, we are ...

The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...